Collectively, we suggest that IL‐25/IL‐17BR axis is highly activated in patients with IPF, which exerts pro‐fibrotic effect via acting on IL‐17BR+‐ILC2 and ‐myofibroblast. Here, IL25 is linked to idiopathic pulmonary fibrosis.